Is bupropion sustained‑release 150 mg twice daily preferable to bupropion extended‑release 300 mg once daily for an adult patient?

Bupropion SR 150 mg Twice Daily vs. XL 300 mg Once Daily

For most adult patients, bupropion SR 150 mg twice daily and bupropion XL 300 mg once daily are therapeutically equivalent in efficacy and safety, but XL 300 mg once daily offers superior medication adherence and should be preferred unless specific clinical factors favor twice-daily dosing. 1, 2

Therapeutic Equivalence

Bioequivalence and efficacy:

• The FDA label confirms that bupropion XL 300 mg once daily is bioequivalent to bupropion SR 150 mg twice daily (total 300 mg/day), demonstrating equivalent peak plasma concentration and area under the curve for both the parent drug and all three active metabolites (hydroxybupropion, threohydrobupropion, and erythrohydrobupropion). 3
• Both formulations achieve the same total daily dose of 300 mg, which is the standard therapeutic target for major depressive disorder and smoking cessation. 1
• Clinical trials demonstrate that 300 mg/day (whether delivered as SR twice daily or XL once daily) produces superior antidepressant response compared with 150 mg/day, with remission rates of 42–49% for depression. 1, 4

Seizure risk is identical:

• At the 300 mg/day dose, seizure incidence is approximately 0.1% (1 in 1,000 patients) for both formulations when patients are appropriately screened for predisposing factors. 1, 5, 6
• The maximum daily dose must not exceed 450 mg/day for XL or 400 mg/day for SR to maintain this low seizure risk. 1

Adherence Advantage of XL Formulation

Once-daily dosing dramatically improves persistence:

• A large U.S. prescription database study (n=269,517) found that 60.1% of patients on bupropion XL had ≥1 refill over one year compared with only 51.3% on bupropion SR (P<0.0001). 2
• The percentage of patients with ≥6 refills over one year was 25.3% with XL versus only 9.5% with SR, indicating that twice-daily dosing leads to premature discontinuation. 2
• The medication possession ratio over nine months was 0.26 for XL compared with 0.16 for SR, demonstrating that once-daily dosing results in better real-world adherence. 2

This adherence difference is clinically meaningful because:

• Approximately 38% of patients fail an initial antidepressant trial, and premature discontinuation before the required 6–8 week therapeutic window contributes to apparent treatment failure. 1
• For smoking cessation, treatment must continue for 7–12 weeks after the quit date to achieve optimal abstinence rates; poor adherence undermines efficacy. 1

Side-Effect Profiles Are Equivalent

Adverse events occur at similar rates:

• A direct head-to-head comparison in cancer patients (n=648) found no significant differences in spontaneously reported adverse events between XL and SR formulations. 7
• The most common side effects—insomnia, dry mouth, headache, nausea, and anxiety—occur with similar frequency in both formulations, with only insomnia and dry mouth occurring significantly more often than placebo. 5
• Discontinuation rates due to adverse events are low (6–12%) and comparable between formulations. 5

Timing strategies to minimize insomnia apply to both:

• For SR formulation, the second dose must be administered before 3 PM to reduce insomnia risk. 1
• For XL formulation, the single morning dose leverages bupropion's activating properties while avoiding late-day stimulation. 1

When to Choose SR Over XL

SR 150 mg twice daily may be preferred in specific scenarios:

1. Dose titration in high-risk populations:

   • Older adults (≥65 years) should start at 37.5 mg every morning and increase by 37.5 mg every 3 days, targeting a maximum of 150 mg twice daily (300 mg total); this gradual titration is easier to implement with SR formulation. 1
   • Patients with moderate-to-severe hepatic impairment require a maximum dose of 150 mg daily (one SR tablet), making SR the only viable option. 1
   • Patients with moderate-to-severe renal impairment (eGFR <90 mL/min) require a 50% dose reduction; SR allows more flexible dosing adjustments. 1

2. Flexible dose adjustment for side effects:

   • If a patient experiences intolerable activation or agitation on XL 300 mg, reducing to SR 150 mg once daily (rather than splitting XL) provides a smoother dose reduction. 1

3. Historical bioequivalence concerns:

   • Some generic versions of bupropion SR were previously found not bioequivalent to brand-name Wellbutrin SR; if a patient has documented loss of efficacy when switching formulations, maintaining the original formulation (whether SR or XL) is prudent. 1

Practical Prescribing Algorithm

For a typical adult patient without contraindications:

1. Initiate bupropion XL 150 mg once daily in the morning for 3 days. 1
2. Increase to XL 300 mg once daily on day 4 if tolerated. 1
3. Assess efficacy at 6–8 weeks; if inadequate response, consider augmentation with an SSRI rather than increasing bupropion dose. 1

For older adults or patients with hepatic/renal impairment:

1. Start bupropion SR 37.5–50 mg once daily in the morning. 1
2. Increase by 37.5 mg every 3 days as tolerated, with the second dose before 3 PM. 1
3. Target a maximum of 150 mg twice daily (300 mg total) for older adults, or 150 mg daily for moderate-to-severe hepatic impairment. 1

Critical Safety Screening Before Either Formulation

Absolute contraindications (apply equally to SR and XL):

• History of seizure disorder or any condition predisposing to seizures (head trauma, brain tumor, stroke). 1
• Current or recent MAOI use (within 14 days). 1
• Eating disorders (bulimia or anorexia nervosa) due to increased seizure risk. 1
• Abrupt discontinuation of alcohol, benzodiazepines, or antiepileptic drugs. 1
• Uncontrolled hypertension (bupropion can elevate blood pressure and heart rate). 1

Monitoring parameters for both formulations:

• Blood pressure and heart rate at baseline and periodically during the first 12 weeks. 1
• Suicidal ideation and behavioral changes, especially in patients <24 years, during the first 1–2 weeks (highest risk period). 1

Common Pitfalls to Avoid

• Do not switch between SR and XL formulations without close monitoring, as historical bioequivalence issues may lead to loss of antidepressant effect. 1
• Do not exceed 300 mg/day for smoking cessation to maintain seizure risk at 0.1%. 1
• Do not discontinue before 6–8 weeks at therapeutic doses unless significant adverse effects occur, as premature discontinuation leads to missed opportunities for response. 1
• Do not prescribe SR without counseling patients to take the second dose before 3 PM, as late-day dosing increases insomnia risk. 1